These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7534752)

  • 1. A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma.
    Grever MR; Benedetti J; Balcerzak SP; Taylor SA; Miller TP; Dakhil SR
    Invest New Drugs; 1994; 12(3):259-61. PubMed ID: 7534752
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group Study.
    Von Hoff DD; Green S; Alberts DS; Stock-Novack DL; Surwit EA; Miller TP; Stephens RL
    Am J Clin Oncol; 1991 Jun; 14(3):193-4. PubMed ID: 1709556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study.
    Von Hoff DD; Dahlberg S; Hartstock RJ; Eyre HJ
    J Natl Cancer Inst; 1990 Aug; 82(16):1353-5. PubMed ID: 1696322
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II evaluation of fludarabine in patients with metastatic breast cancer: a Southeastern Cancer Study Group trial.
    Carpenter JT; Vogel CL; Wang G; Raney M
    Cancer Treat Rep; 1986 Oct; 70(10):1235-6. PubMed ID: 2428493
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study.
    Balducci L; Blumenstein B; Von Hoff DD; Davis M; Hynes HE; Bukowski RM; Crawford ED
    Cancer Treat Rep; 1987 May; 71(5):543-4. PubMed ID: 2436773
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study.
    Von Hoff DD; Green S; Surwit EA; Hannigan EV; Alberts DS
    Am J Clin Oncol; 1990 Oct; 13(5):433-5. PubMed ID: 1699401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine phosphate. Phase II evaluation in advanced soft-tissue sarcomas.
    Pazdur R; Samson MK; Baker LH
    Am J Clin Oncol; 1987 Aug; 10(4):341-3. PubMed ID: 2441592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study.
    Kraut EH; Crowley JJ; Grever MR; Keppen MD; Bonnet JD; Hynes HE; Salmon SE
    Invest New Drugs; 1990 May; 8(2):199-200. PubMed ID: 1696569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study.
    Kish JA; Kopecky K; Samson MK; Von Hoff DD; Fletcher WS; Kempf RA; Muggia FM
    Invest New Drugs; 1991 Feb; 9(1):105-8. PubMed ID: 1709151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.
    Grever MR; Kopecky KJ; Coltman CA; Files JC; Greenberg BR; Hutton JJ; Talley R; Von Hoff DD; Balcerzak SP
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):457-9. PubMed ID: 2464793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of fludarabine in patients with epithelial ovarian cancer.
    Kavanagh JJ; Stringer CA; Copeland LJ; Gershenson DM; Saul P
    Cancer Treat Rep; 1986 Mar; 70(3):425-6. PubMed ID: 2420446
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor lysis syndrome induced by fludarabine monophosphate: a case report.
    Nakhoul F; Green J; Abassi ZA; Carter A
    Eur J Haematol; 1996 Apr; 56(4):254-5. PubMed ID: 8641396
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I study of fludarabine (2-fluoro-ara-AMP).
    Kavanagh JJ; Krakoff IH; Bodey GP
    Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1009-11. PubMed ID: 2415365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary toxicity associated with fludarabine monophosphate.
    Hurst PG; Habib MP; Garewal H; Bluestein M; Paquin M; Greenberg BR
    Invest New Drugs; 1987; 5(2):207-10. PubMed ID: 2443463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial.
    Taylor SA; Crowley J; Vogel FS; Townsend JJ; Eyre HJ; Jaeckle KA; Hynes HE; Guy JT
    Invest New Drugs; 1991 May; 9(2):195-7. PubMed ID: 1714887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.
    Shevrin DH; Lad TE; Kilton LJ; Cobleigh MA; Blough RR; Weidner LL; Vogelzang NJ
    Invest New Drugs; 1989 Jul; 7(2-3):251-3. PubMed ID: 2477345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. An Illinois Cancer Center study.
    Kilton LJ; Benson AB; Greenberg A; Johnson P; Shapiro C; Blough R; French S; Weidner L
    Invest New Drugs; 1992 Aug; 10(3):201-4. PubMed ID: 1385353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of fludarabine phosphate in small cell carcinoma. A Southwest Oncology Group Study.
    Rainey JM; Hill JB; Crowley J
    Invest New Drugs; 1988 Apr; 6(1):45-6. PubMed ID: 2457565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate.
    Kane GC; McMichael AJ; Patrick H; Erslev AJ
    Respir Med; 1992 May; 86(3):261-3. PubMed ID: 1377831
    [No Abstract]   [Full Text] [Related]  

  • 20. Fludarabine phosphate therapy of non-Hodgkin's lymphoma.
    Hochster H; Cassileth P
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):63-5. PubMed ID: 1699284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.